Skip to content
HowShorted

KalVista Pharmaceuticals, Inc. short interest in 2021

In 2021, KalVista Pharmaceuticals, Inc.'s disclosed short interest ran from 2.23% of shares outstanding on 15 Jan 2021 to 3.87% on 31 Dec 2021, a change of +1.64 percentage points. The year's high was 8.21% on 30 Jun 2021 and its low 2.23% on 15 Jan 2021, averaging 5.18% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.44 days on 13 Aug 2021. Full history: KalVista Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for KalVista Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
2.23% (15 Jan 2021)
End of year
3.87% (31 Dec 2021)
Change
+1.64 pp
High
8.21% (30 Jun 2021)
Low
2.23% (15 Jan 2021)
Average
5.18%
Highest days to cover
18.44 (13 Aug 2021)
SEC filings marked
9

Every report in 2021

KalVista Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20212.23%3.25
29 Jan 20212.86%4.71
12 Feb 20213.57%1.00results (8-K)
26 Feb 20214.36%1.51
15 Mar 20213.20%2.3710-Q filed, results (8-K)
31 Mar 20214.86%2.70
15 Apr 20215.35%4.13
30 Apr 20215.52%3.14
14 May 20215.90%6.78
28 May 20215.67%6.77
15 Jun 20215.89%10.81
30 Jun 20218.21%4.46
15 Jul 20218.02%9.1610-K filed, results (8-K)
30 Jul 20217.88%10.32
13 Aug 20217.58%18.44
31 Aug 20217.21%12.91
15 Sep 20215.69%10.1410-Q filed, results (8-K)
30 Sep 20214.85%3.84
15 Oct 20215.04%5.53
29 Oct 20214.44%5.42
15 Nov 20214.23%9.19
30 Nov 20213.95%4.87
15 Dec 20213.86%3.3210-Q filed, results (8-K)
31 Dec 20213.87%4.22

See also: KalVista Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.